IDEXX Laboratories, Inc. $IDXX Stock Holdings Lifted by Alta Capital Management LLC

Alta Capital Management LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,143 shares of the company’s stock after buying an additional 1,253 shares during the period. Alta Capital Management LLC’s holdings in IDEXX Laboratories were worth $11,876,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Mutual Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth about $244,000. Harbour Investments Inc. lifted its position in shares of IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after buying an additional 21 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc lifted its position in shares of IDEXX Laboratories by 50.6% in the second quarter. AEGON ASSET MANAGEMENT UK Plc now owns 48,308 shares of the company’s stock worth $25,887,000 after buying an additional 16,237 shares during the last quarter. Aries Wealth Management lifted its position in shares of IDEXX Laboratories by 2.5% in the second quarter. Aries Wealth Management now owns 3,172 shares of the company’s stock worth $1,701,000 after buying an additional 76 shares during the last quarter. Finally, Sagespring Wealth Partners LLC lifted its position in shares of IDEXX Laboratories by 38.7% in the second quarter. Sagespring Wealth Partners LLC now owns 756 shares of the company’s stock worth $406,000 after buying an additional 211 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company’s stock, valued at $4,477,041.68. This represents a 54.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Nimrata Hunt sold 7,143 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. UBS Group assumed coverage on IDEXX Laboratories in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price target for the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research report on Monday, August 4th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Finally, Piper Sandler reissued a “neutral” rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $639.15 on Thursday. The stock has a 50-day simple moving average of $640.70 and a 200 day simple moving average of $546.36. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market capitalization of $51.13 billion, a PE ratio of 53.22, a P/E/G ratio of 4.12 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.